您当前的位置:国际号刊-季刊 > 高T3 > AMI入库 > 金融保险 >
中国金融评论(英文)(China Finance Review International)(国际刊号)

中国金融评论(英文)(China Finance Review International)(国际刊号)

  • 高T3
  • AMI入库
基本信息
  • 主管单位:

  • 主办单位:

    上海交通大学安泰经济与管理学院

  • 国际刊号:

    2044-1398

  • 国内刊号:

  • 学科分类:

    金融保险

  • 字数:

    -

  • 有无基金:

     

  • 周期:

    国际号刊-季刊

  • 特殊属性:

    外文期刊

联系信息
  • 电话:

    021-52301267(官网电话)

  • 邮箱:

    cfr@sjtu.edu.cn(官网邮箱)

  • 复合因子:

    0

  • 综合因子:

    0

  • 收录:

  • 级别:

    高T3,AMI入库

期刊简介

《中国金融评论(英文)(China Finance Review International)(国际刊号)》期刊已被查看:

更新频次

单位占比

一作占比

投稿指南

1、该刊只有国际刊号。

2、投稿方式:在线投稿。

3、官网网址:

https://www.emeraldgrouppublishing.com/journal/cfri

https://www.emeraldgrouppublishing.com/cfri.htm

4、投稿系统:

https://preflight-submit.paperpal.com/partner/emerald/chinafinrevint/submit

https://mc.manuscriptcentral.com/cfri

5、主办单位网址:

https://www.acem.sjtu.edu.cn/faculty/academic.html

https://www.acem.sjtu.edu.cn/news_center/news/45212.html

(上海交通大学安泰经济与管理学院)

6、官网邮箱:cfr@sjtu.edu.cn

7、官网电话:021-52301267

8、出刊日期:季刊,一年出版4期。

9、微信公众号:中国金融评论(CFRI-SJTU)

2021年9月30日星期四

《中国金融评论(英文)》期刊简介

(China Finance Review International)

【上海交通大学安泰经济与管理学院官网信息】

China Finance Review International(CFRI,中国金融评论)创刊于2007年,是由上海交通大学安泰经济与管理学院创办的一本反映中国经济、金融最前沿研究成果的全英文学术期刊。

期刊致力于发表关于金融和经济问题的高质量的实证和理论研究,鼓励金融领域相关的开创性研究,例如金融科技和社会责任投资等。批判性思维亦是本刊强调的一个关键领域。目前CFRI期刊已被多个权威数据库收录:Scopus、Web of Science Emerging Sources Citation Index (ESCI)、ABI/INFORM Complete、Cabell's Dictionary、ProQuest、EBSCO、Summon、RePEc、Econlit,进入ABDC和Association of Business Schools' (ABS) Academic Journal Guide等一系列评级列表。期刊2019年度在SCOPUS中的CiteScore为1.76。

期刊网站:https://www.emeraldgrouppublishing.com/cfri.htm

电子邮箱:cfr@sjtu.edu.cn

联系电话:021-52301267

《中国金融评论(英文)》作者指南

(China Finance Review International)

【官网信息】

Author guidelines

Before you start

For queries relating to the status of your paper pre decision, please contact the Editor or Journal Editorial Office. For queries post acceptance, please contact the Supplier Project Manager. These details can be found in the Editorial Team section.

Author responsibilities

Our goal is to provide you with a professional and courteous experience at each stage of the review and publication process. There are also some responsibilities that sit with you as the author. Our expectation is that you will:

Respond swiftly to any queries during the publication process.

Be accountable for all aspects of your work. This includes investigating and resolving any questions about accuracy or research integrity

Treat communications between you and the journal editor as confidential until an editorial decision has been made.

Read about our research ethics for authorship. These state that you must:

Include anyone who has made a substantial and meaningful contribution to the submission (anyone else involved in the paper should be listed in the acknowledgements).

Exclude anyone who hasn’t contributed to the paper, or who has chosen not to be associated with the research.

If your article involves human participants, you must ensure you have considered whether or not you require ethical approval for your research, and include this information as part of your submission. Find out more about informed consent.

Research and publishing ethics

Our editors and employees work hard to ensure the content we publish is ethically sound. To help us achieve that goal, we closely follow the advice laid out in the guidelines and flowcharts on the COPE (Committee on Publication Ethics) website.

We have also developed our research and publishing ethics guidelines. If you haven’t already read these, we urge you to do so – they will help you avoid the most common publishing ethics issues.

A few key points:

Any manuscript you submit to this journal should be original. That means it should not have been published before in its current, or similar, form. Exceptions to this rule are outlined in our pre-print and conference paper policies.  If any substantial element of your paper has been previously published, you need to declare this to the journal editor upon submission. Please note, the journal editor may use Crossref Similarity Check to check on the originality of submissions received. This service compares submissions against a database of 49 million works from 800 scholarly publishers.

Your work should not have been submitted elsewhere and should not be under consideration by any other publication.

……

更多详情:

https://www.emeraldgrouppublishing.com/journal/cfri#author-guidelines

中国全科医学发文选摘

  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

常见问题

  • 哪些期刊可以用来评职称?

    1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。

  • 你们的服务可以保证文章被发表吗?

    期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。

  • 请问发表一篇期刊的费用是多少?

    期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。

  • 如果发表不成功可以退款吗?

    如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。

  • 请问文章发表需要多长时间?

    不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。

  • 期刊发表能加急见刊吗?

    为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。